Biomarkers are common in advanced lung cancer, and many can be targeted with approved medicines
Fewer than half (37%) of patients with advanced lung cancer receive comprehensive biomarker testing,[1] even though studies have shown that lung cancer patients who receive a targeted therapy based on their biomarker testing results may have better outcomes than those who do not.
[1] Robert NJ, et al. Biomarker testing and tissue journey among patients with metastatic non-small cell lung cancer receiving first-line therapy in The US Oncology Network. Lung Cancer. Vol. 166, pages 197-204. Open Access here: https://www.sciencedirect.com/science/article/pii/S0169500222003737?via%3Dihub
